Wellington Management Group LLP Buys Shares of 1,583,154 Upstream Bio, Inc. (NASDAQ:UPB)

Wellington Management Group LLP purchased a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,583,154 shares of the company's stock, valued at approximately $25,632,000. Wellington Management Group LLP owned about 2.95% of Upstream Bio as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in UPB. BNP Paribas Financial Markets purchased a new position in Upstream Bio in the fourth quarter worth about $25,000. US Bancorp DE bought a new stake in shares of Upstream Bio during the fourth quarter valued at approximately $27,000. Legal & General Group Plc bought a new stake in shares of Upstream Bio during the fourth quarter valued at approximately $28,000. Summit Investment Advisors Inc. purchased a new position in Upstream Bio in the 4th quarter worth approximately $30,000. Finally, Tower Research Capital LLC TRC bought a new position in Upstream Bio in the 4th quarter valued at approximately $47,000.

Upstream Bio Stock Performance

UPB traded up $0.18 during trading on Tuesday, hitting $10.84. 390,162 shares of the company's stock traded hands, compared to its average volume of 335,364. The company's 50 day simple moving average is $8.25 and its two-hundred day simple moving average is $11.57. Upstream Bio, Inc. has a 12-month low of $5.14 and a 12-month high of $29.46.

Upstream Bio (NASDAQ:UPB - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.02). The company had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.71 million. Research analysts anticipate that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.